hospital formulary decisions, Optimer's ability to successfully coordinate commercialization efforts with Cubist under its co-promotion agreement, whether Optimer will be able to realize expected benefits under its co-promotion agreement with Cubist and its collaboration agreements with other partners, the possibility of alternative means of preventing or treating CDAD impacting adoption and sales of DIFICID, Optimer's ability, through its third-party manufacturers and logistics providers, to maintain a sufficient supply of DIFICID to meet demand, the effects of changes in Optimer's management, the outcome of Optimer's review of strategic alternatives including a possible sale of the Company, the potential for lawsuits and enforcement proceedings related to the previously disclosed investigations by U.S. authorities and other risks detailed in Optimer's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this release, and Optimer undertakes no obligation to update or revise these statements, except as may be required by law.
Contacts Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
Jason I. Spark, Senior Vice President
Optimer Pharmaceuticals, Inc.Consolidated Statements of Operations and Comprehensive Loss Three Months Ended Years Ended December 31, December 31, 2012201120122011(unaudited)(unaudited)Revenues:Product sales, net
19,515,67664,616,356101,531,429144,978,373Cost and expenses:Cost of product sales
1,364,656909,8435,486,2391,525,798Cost of contract revenue
1,652,0083,310,8216,462,9397,584,353Research and development<
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Optimer Pharmaceuticals Board of Directors Appoints Board Chairman, Dr. Henry McKinnell, Chief Executive Officer2
. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results3
. Optimer Pharmaceuticals to Present at Leerink Swann Global Healthcare Conference4
. Optimer Pharmaceuticals to Present at 23rd Annual Oppenheimer Healthcare Conference5
. Optimer Pharmaceuticals to Present at November 2012 Investor Conferences6
. Optimer Pharmaceuticals Reports Third Quarter 2012 Financial Results7
. Optimer Pharmaceuticals to Present at September 2012 Investor Conferences8
. Optimer Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference9
. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors10
. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2012 Financial Results11
. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference